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Abstract
Hepatitis C infection is universal and the most common 
indication of liver transplantation in the United States. 
The period of less effective interferon therapy with 
intolerable side effects has gone. Now we have stepped 
into the era of direct acting anti-viral agents (DAAs) 
against hepatitis C virus. Treatment of hepatitis C is 
now extremely effective, tolerable and requires a short 
duration of intake of oral agents. Less monitoring 
is required with the current therapy and drug-drug 
interactions are less than the previous regimen. The 
current treatment options of chronic hepatitis C with 
various DAAs are discussed in this article.
Key words: Direct acting anti-viral agents; Hepatitis C 
virus infection; Post-liver transplant; Hepatitis C virus/
human immunodeficiency virus co-infection
© The Author(s) 2018. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: Treatment of hepatitis C has now become 
much easy and simple with the advent of direct acting 
anti-viral agents (DAAs) against hepatitis C virus (HCV). 
Although the DAAs are highly effective in eradicating 
HCV infection, they have different mechanisms of 
action, side effects, resistance factors and drug-
drug interactions. The treatment also varies in special 
situations like HCV/ human immunodeficiency virus co-
infection and post-liver transplant patients. Physicians 
treating patients with HCV infection should have a 
clear knowledge about the DAAs as well as the current 
guidelines. 
Ahmed M. Era of direct acting anti-viral agents for the treatment 
of hepatitis C. World J Hepatol 2018; 10(10): 670-684  Available 
from: URL: http://www.wjgnet.com/1948-5182/full/v10/i10/670.
htm  DOI: http://dx.doi.org/10.4254/wjh.v10.i10.670
INTRODUCTION
Chronic hepatitis C infection is common in the United 
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States and throughout the world. About 3 million 
people in the United States and 177.5 million people 
in the world suffer from chronic hepatitis C infection[1]. 
Hepatitis C virus (HCV) contains structural proteins - 
core or C protein, E1 and E2 envelope proteins, and 
nonstructural proteins - P7, NS2, NS3, NS4A, NS4B, 
NS5A and NS5B[2]. HCV contains error prone RNA 
dependent RNA polymerase and mutation is present 
during each viral replication[3]. As a result, HCV exists 
as a quasispecies characterized by the presence of 
various genetically distinct variants which protect the 
HCV from host defenses as well as anti-HCV agents[4]. 
DAA are specific antiviral agents targeting the critical 
steps of HCV replication. With the development of direct 
acting anti-viral agent (DAA), the treatment of chronic 
hepatitis C has been completely revolutionized. In 1990’s 
when we had only Interferon therapy, the sustained 
virological response (SVR) was 17% with many side 
effects[5]. Then Pegylated Interferon and Ribavirin came 
after few years but still the SVR was 40% to 50%[6]. In 
2011, the first generation NS3/4A protease inhibitors 
(Telaprevir and Boceprevir) were launched to be used 
with pegylated interferon and ribavirin for the treatment 
of hepatitis C genotype 1 infection. The SVR improved to 
about 70% at the expense of many side effects, drug-
drug interactions and complex regimen of administration 
of medications and cost[7]. Now we have 2nd generation 
NS3/4A protease inhibitors, NS5A inhibitors and NS5B 
inhibitors. They have markedly improved the efficacy of 
treatment of HCV infection. The different DAAs with their 
dose, efficacy, side effects, drug-drug interactions as well 
as specific treatment against different genotypes of HCV 
will be discussed in the following sections (Figure 1).
NS3/4A protease inhibitors
HCV NS3/4A is a multifunctional protein composed 
of a membrane-targeted serine protease domain and 
a helicase domain. NS3/4A protease is responsible 
for maturation of a viral polyprotein that cleaves and 
generates NS3, NS4A, NS4B, NS5A and NS5B. Thus 
NS3/4A protease is essential for viral replication[8]. 
NS3/4A protease inhibitors (PIs) are classified into first 
generation PIs and second generation PIs[9]. The first 
generation PIs include boceprevir and telaprevir. They 
are no longer used in clinical practice. The second gene-
ration PIs includes simeprevir, paritaprevir, grazoprevir, 
glecaprevir and voxilaprevir. They are highly potent 
DAAs but they have low barrier to resistance and limited 
genotypic coverage.
Simeprevir is a once daily macrocyclic 2nd - waive 
NS3/4A protease inhibitor approved to be used with 
pegylated interferon and ribavirin for the treatment 
of chronic hepatitis C genotype 1 patients in 2013. In 
QUEST-1 and QUEST-2 trials (simeprevir + PEG + RBV 
vs PEG + RBV in treatment-naïve genotype 1 patients), 
80% to 81% of treatment-naïve patients achieved 
SVR12, i.e., negative viral load 12 wk after completion 
of treatment[10,11]. Patients who had Q80K polymorphism 
had only 58% SVR12. In PROMISE trial, Simeprevir was 
given with pegylated interferon and ribavirin to treatment 
(Interferon)-experienced hepatitis C genotype 1 patients. 
The SVR12 was 79.2%. The SVR 12 also varied with 
the host IL28B genotype. Patient’s IL28B genotype is 
involved in the host immune response to HCV infection. 
There are 3 IL28B subtypes: CC, CT and TT. The IL28B 
CC genotypes had the highest response and the IL28B 
TT genotypes had the lowest response[12]. In COSMOS 
trial, combination of simeprevir and sofosbuvir (NS5B 
inhibitor) with or without ribavirin were given to HCV 
genotype 1 infected patients - both treatment-naïve 
patients and non-responders to pegylated interferon 
and ribavirin for 12 wk and 24 wk. Ninety-two percent 
to 94% of patients achieved SVR12[13]. In OPTIMIST-1 
trial, combination of simeprevir and sofosbuvir was 
given to treatment-naïve non-cirrhotic HCV genotype 1 
infected patients. Ninety-seven percent of patients who 
received this combination achieved SVR12 in the 12 wk 
arm whereas only 83% achieved SVR12 in the 8-wk 
arm[14]. In OPTIMIST-2 trial, cirrhotic patients due to HCV 
genotype 1 infection received combination of simeprevir 
and sofosbuvir for 12 wk. SVR12 was achieved in 83% 
of patients: 88% in treatment-naïve patients and 79% in 
treatment-experienced patients[15].
The main side effects of Simeprevir include headache, 
fatigue, nausea, photosensitivity and skin rash[16]. 
Latent HBV infection could be reactivated if patient is 
on simeprevir. Simprevir can also cause hepatic failure 
if used in decompensated cirrhosis of liver. Simeprevir 
has sulphur moiety which may cause sulphur allergy. 
Patients on simeprevir should not take moderate to high 
intensity enzyme-inducers or enzyme-inhibitors as they 
may decrease or increase the serum levels of simeprevir. 
Prior to the use of Simeprevir, it is recommended to do 
Q80K polymorphism screening (HCV GenoSure NS3/4A 
Assay) which has been found in 35% of patients infected 
with HCV genotype 1, and in more than 40% of patients 
infected with HCV genotype 1a[17]. In the Interferon free 
era, combination of simeprevir 150 mg/d and sofosbuvir 
400 mg/d for 12 wk is recommended as an alternative 
regimen in the treatment of treatment-naïve genotype 
1a or 1b patients without cirrhosis as per the American 
Association for the Study of Liver Diseases (AASLD). 
Drug-drug interactions: Common medications which 
are not recommended to be co-administered with Si-
meprevir include systemic antibiotics like clarithromycin, 
erythromycin, systemic antifungals like fluconazole, 
ketoconazole, itraconazole, antimycobacterials like 
rifampin, rifabutin, anti-hepatitis C medication ledipasvir, 
anti-human immunodeficiency virus (HIV) medications 
like ritonavir, darunavir, efavirenz, nevirapine, etravirine, 
delavirdine, atazanavir, nelfinavir, saquinavir, indinavir, 
fosamprenavir, tipranavir, anti-arrhythmic drug like 
amiodarone, anticonvulsants like phenytoin, pheno-
barbital, carbamazepine, dexamethasone, cyclosporine, 
milk thistle and St. John’s Wort[18].
Paritaprevir is a macrocyclic NS3/4A protease 
inhibitor used in combination with low dose ritonavir 
which is a strong CYP3A inhibitor, and thus increases 
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antimycobacterial medication rifampin, antipsychotic 
medication lurasidone and pimozide, ergot agents 
methylergonovine, ergotamine and dihydroergotamine, 
ethinyl estradiol containing medications, prokinetic 
agent cisapride, herbal agent St. John’s Wort, immunosu-
ppressive agents tacrolimus, sirolimus and everolimus, 
and anti-HIV medication efavirenz[24].
Grazoprevir is a macrocyclic NS3/4A serine protease 
inhibitor against HCV genotype 1 and 4. It is used 
in combination with Elbasvir (NS5A inhibitor) for the 
treatment of HCV genotypes 1 and 4. In clinical trials, 
combination of elbasvir and grazoprevir (Zepatier) has 
been shown to achieve SVR in 94% to 97% of cases 
of genotype 1 infection and 97% to 100% of cases of 
genotype 4 infection. The overall SVR for non-cirrhotics 
was 97% and for cirrhotics 95.7%[25]. The regimen was 
effective in stage 4 to 5 chronic kidney disease[26]. In 
case of HCV genotype 1a infection, NS5A resistance 
testing should be done prior to initiation of elbasvir and 
grazoprevir therapy. In 10% to 15% of cases, NS5A 
polymorphism is positive and in that case weight-
based ribavirin (less than 66 kg = 800 mg/d, 66 to 80 
kg = 1000 mg/d, 81 to 105 kg = 1200 mg/d, greater 
than 105 kg = 1400 mg/d administered in two divided 
doses with food) should be added and the duration 
should be increased from 12 to 16 wk. Otherwise HCV 
genotype 1a or 1b infection requires only 12 wk of 
Zepatier therapy irrespective of exposure to pegylated 
interferon and ribavirin (PEG/RIBA), and presence of 
cirrhosis of liver. In case of HCV genotype 4 infection, the 
duration of Zepatier therapy is 12 wk for treatment-naïve 
patients, but it should be extended to 16 wk if PEG/RIBA 
experienced with prior on-treatment virologic failure[27]. 
In C-ISLE study, Elbasvir/Grazoprevir plus Sofosbuvir was 
given to patients with compensated cirrhosis due to HCV 
genotype 3 infection for 12 wk. The SVR12 was 96% in 
treatment-naïve patients and 100% in PEG-interferon/
Ribavirin experienced patients[28]. HBV reactivation can 
occur on grazoprevir/elbasvir therapy if the patient is co-
infected with HBV and not receiving anti-HBV therapy. 
HBV serology (HBsAg and anti-HBc) and HCV resistance 
peak and trough level of Paritaprevir[19]. Paritaprevir/
ritonavir-ombitasvir (NS5A inhibitor) - a 3 drug fixed 
dose combination tablet co-packaged with dasabuvir 
(NS5B inhibitor) tablet in Viekira Pak, and dasabuvir, 
ombitasvir, paritaprevir and ritonavir - a 4 drug fixed 
dose combination tablet in Viekira XR with or without 
ribavirin are approved for the treatment of chronic hepa-
titis C genotype 1[20]. Paritaprevir/ritonavir-ombitasvir 
(in TECHNIVIE) with ribavirin is approved for the 
treatment hepatitis C genotype 4 without cirrhosis of 
liver. Viekira Pak and Viekira XR carry a higher pill burden 
than other regimen. They are also contraindicated in 
advanced cirrhosis of liver (Child-Pugh B and C). They 
are metabolized mainly in the liver. As a result, no 
dose adjustment is needed even in severe renal failure 
including those on dialysis[21]. If the patient has HBV/HCV 
co-infection and not receiving HBV antiviral therapy, HBV 
reactivation can occur leading to severe hepatitis, hepatic 
failure and death. In RUBY-1 trial, 90% of patients 
with HCV genotype 1 infection and end-stage renal 
disease (CKD 4 and CKD 5) had SVR12, i.e., negative 
serum HCV RNA after 12 wk of therapy with dasabuvir, 
ombitasvir, paritaprevir and ritonavir[22]. In case of HCV 
genotype 1a infection - Viekira should be continued for 
12 wk in non-cirrhotics and 24 wk in cirrhotics. In case of 
HCV genotype 1b infection - Viekira should be given for 
12 wk irrespective of cirrhosis or non-cirrhosis status[23]. 
In liver transplant recipients with normal liver function 
and mild hepatic fibrosis, Viekira pak or Viekira XR with 
weight-based ribavirin should be given for 24 wk. The 
common side effects of Viekira include nausea, insomnia, 
itching and asthenia. 
Drug-drug interaction: Common medications which 
are contra-indicated with Viekira include lipid lowering 
agent gemfibrozil, HMG co-reductase inhibitors - 
simvastatin, atorvastatin, lovastatin, anti-arrhythmic 
drug dronedarone, α-1 adrenoreceptor blocker alfuzosin, 
anti-anginal medication ranolazine, phosphodiesterase 
inhibitor sildenafil, anticonvulsants like phenytoin, 
phenobarbital, carbamazepine, sedative/hypnotics 
triazolam, midazolam, anti-gout medication colchicine, 
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associated polymorphisms as mentioned before should 
be tested prior to initiation of Zepatier therapy. Common 
side effects include headache, nausea and fatigue[29]. 
Common medications which are not recommended 
to be used with Zepatier include antibiotic Nafcillin, 
antifungal oral ketoconazole, anti-HIV medication etra-
virine, cobicistat containing medications like tenofovir, 
emtricitabine, cobicistat, HMG Co-A reductase inhibitors 
atorvastatin (dose should not exceed > 20 mg/d), 
rosuvastatin (dose should not exceed > 10 mg/d), 
simvastatin, lovastatin, fluvastatin (should be closely 
monitored for myopathy), nacolepsy medication moda-
finil, immunosuppressant tacrolimus, and endothelin an-
tagonist bosentan[29].
Drug-drug interaction: Glecaprevir is a NS3/4A 
protease inhibitor coformulated with NS5A inhibitor 
pibrentasvir (Mavyret). Glecaprevir-pibrentasvir combi-
nation has been shown to have pangenotypic anti-
HCV activity. In EXPEDITION-1 study, glecaprevir 
(300 mg) - pibrentasvir (120 mg) coformulation when 
given daily for 12 wk to treatment-naïve or treatment 
experienced (pegylated interferon plus ribavirin or 
sofosbuvir plus ribavirin) patients with HCV genotypes, 
infection and compensated cirrhosis, 99% of patients 
achieved SVR at 12 wk[30]. Another study showed 
glecaprevir-pibrentasvir combination when given for 
8 wk to patients with HCV genotype-1 and 3 infection 
had SVR 12 of 99.1% and 95% respectively[31]. Patients 
with chronic kidney disease (CKD) have more chronic 
hepatitis C, particularly in patients on hemodialysis, 
8.4% hemodialysis patients had chronic hepatitis C 
in the year of 2000. When patients with severe renal 
failure (stage 4 or 5 CKD or dialysis dependence) 
and HCV genotype 1, 2, 3, 4, 5 or 6 infection with or 
without compensated cirrhosis, treatment-naïve or 
treatment-experienced (pegylated interferon, ribavirin, 
sofosbuvir or a combination of these medications), were 
treated with glecaprevir-pibrentasvir combination for 
12 wk, they had sustained SVR12 of 98%[32]. No dose 
adjustment was required in patients with severe renal 
failure or in hemodialysis patients[33].
Three tablets of fixed dose Glecaprevir 100 mg/
Pibrentasvir 40 mg (i.e., 300 mg/120 mg total dose) PO 
once daily is given with food.
In treatment-naïve patients[33], the recommended 
duration is 8 wk for genotypes 1 to 6 infection without 
cirrhosis. But the treatment duration is 12 wk for 
genotypes 1 to 6 infection with compensated cirrhosis 
(Child-Pugh A). In treatment-experienced patients. In 
non-cirrhotics: Genotype 1 and NS5A inhibitor prior 
treatment: 16 wk. Genotype 1 and NS3/4A protease 
inhibitor prior treatment: 12 wk. Genotypes 1, 2, 4, 
5, or 6 (prior treatment with boceprevir, or telaprevir 
or simeprevir with pegylated interferon and ribavirin, 
simeprevir and sofosbuvir): 8 wk. Genotype 3 (prior 
treatment with boceprevir, or telaprevir or simeprevir 
with pegylated interferon and ribavirin, simeprevir and 
sofosbuvir): 16 wk.
In treatment-experienced patients[33] with com-
pensated cirrhotics (Child-Pugh A): Genotype 1 and 
NS5A inhibitor prior treatment: 16 wk. Genotype 1 
and NS3/4A protease inhibitor prior treatment: 12 
wk. Genotypes 1, 2, 4, 5, or 6 (prior treatment with 
boceprevir, or telaprevir or simeprevir with pegylated 
interferon and ribavirin, simeprevir and sofosbuvir): 12 
wk. Genotype 3 (prior treatment with, boceprevir, or 
telaprevir or simeprevir with pegylated interferon and 
ribavirin, simeprevir and sofosbuvir): 16 wk. Common 
side effects of Mavyret include headache, fatigue, nausea 
and diarrhea. 
Commonly used medications which can cause 
drug interaction with Mavyret include HMG Co-A re-
ductase inhibitors atorvastatin, lovastatin, simvastatin, 
rosuvastatin, pravastatin, pitavastatin, fluvastatin, 
ethinyl estradiol containing medications, anticoagulant 
dabigatran, antiarrhythmic digoxin, anticonvulsant 
carbamazepine, antimycobacterial rifampin, anti-HIV 
medications efavirenz, ritonavir, lopinavir, darunavir, 
atazanavir, herbal medication St. John’s Wort, and 
immunosuppressant cyclosporine[34].
Voxilaprevir is a NS3/4A protease inhibitor. It is 
used in the fixed dose combination of sofosbuvir and 
velpatasvir (NS5A inhibitor), commercially available as 
Vosevi. In POLARIS-1, sofosbuvir (400 mg)/velpatasvir 
(100 mg)/voxilaprevir (100 mg) single pill was given 
daily for 12 wk to NS5A inhibitor-experienced patients 
with HCV genotype 1-6 infection. In POLARIS-4, 
sofosbuvir/velpatasvir/voxilaprevir was given daily for 
12 wk to DAA experienced (but not NS5A experienced) 
patients with HCV genotype 1-3 infection, and also to 
patients with HCV genotype 4 infection. Forty-six percent 
of all these patients had compensated cirrhosis of liver. 
In POLARIS-1, the SVR was 96%, and in POLARIS-4, 
the SVR was 98%[35]. Currently, Vosevi is approved 
for retreatment of: (1) HCV genotype 1-6 infection 
in adults who were previously treated with an NS5A 
inhibitor-containing regimen; and (2) HCV genotype 
1a or 3 infection in adults who were previously treated 
with sofosbuvir-containing regimen without an NS5A 
inhibitor[36]. Vosevi can be given to patients without 
cirrhosis or with compensated cirrhosis, and no dose 
adjustment is required even in severe renal impairment 
with glomerular filtration rate (GFR) < 30 mL/min or 
end stage renal disease. If the patient is HBV coinfected 
and not receiving anti-HBV therapy, HBV reactivation 
can occur during or after completion of treatment with 
Vosevi. So, serological evidence of HBV infection (HBVsAg 
and anti-HBVc antibody) should be looked for before 
initiation of therapy with Vosevi. Common side effects 
of Vosevi include headache, nausea, diarrhea insomnia, 
asthenia and fatigue.
Drug-drug interaction: Certain medications are not 
recommended with Vosevi. These include anatacids 
like aluminum or magnesium hydroxide, H2 receptor 
antagonists like Famotidine, proton pump inhibitor 
like omeprazole, anticoagulant like dabigatran, anti-
arrhythmic agents like digoxin, amiodarone, HMG Co-A 
reductase inhibitors atorvastatin, lovastatin, fluvastatin, 
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simvastatin, rosuvastatin, pravastatin, pitavastatin, 
anticonvulsants like phenytoin, phenobarbital, carba-
mazepine, oxcarbazepin, anti-HIV medications efavirenz, 
tenofovir, lopinavir, atazanavir, tipranavir/ritonavir, anti-
mycobactrial agents like rifampin, rifabutin, rifapentin, 
immunosuppressant cyclosporine, and herbal supplement 
St. John’s Wort[37].
NS5A inhibitors
Inhibit hyperphosphorylation of NS5A phosphoprotein 
which is necessary for HCV RNA replication, and they also 
cause transfer of NS5A from the endoplasmic reticulum 
to lipid droplets in HCV replicon-containing cells leading 
to significant reduction of HCV RNA in cell culture[38]. 
Ledipasvir, ombitasvir, daclatasvir, elbasvir, velpatasvir 
and pibrentasvir are NS5A inhibitors. They are highly 
potent DAA with multigenetic coverage and intermediate 
barrier to resistance.
Ledipasvir is a NS5A inhibitor used as part of 
combination therapy with Sofosbuvir (NS5B inhibitor) 
for the treatment of chronic hepatitis C. The fixed dose 
combination called Harvoni (90 mg of Ledipasvir and 
400 mg Sofosbuvir) developed by Gilead Sciences was 
approved by the FDA in 2014. 
Effectiveness, duration and need for addition of 
ribavirin with this medication depend on viral load, 
genotype, compensated or decompensated cirrhosis, 
treatment naïve or treatment-experienced status, and 
pre or post-transplant status.
In ION-1 phase 3 clinical trial, 99% of treatment 
naïve patients with chronic hepatitis C genotype 1 who 
received Ledispavir-Sofosbuvir combination for 12 wk 
achieved SVR[39]. In ION-2 phase 3 clinical trial, 99% 
of patients with previously treated genotype-1 HCV 
infection who received Ledispavir-Sofosbuvir combination 
for 24 wk had SVR[40]. Patients with HCV genotype-1 
infection and compensated cirrhosis were studied with 
Ledispavir-Sofosbuvir combination for 12 and 24 wk in 
treatment naïve and treatment experienced patients 
with or without ribavirin[41]. The overall SVR was 96%: 
98% in treatment-naïve group vs 95% in treatment-
experienced group, 95% in 12 wk therapy group vs 
98% in 24 wk therapy group, 95% without ribavirin vs 
97% with ribavirin. The only group who did not do well 
was the treatment-experienced group who received 
Ledispavir-Sofosbuvir combination for only 12 wk and 
without ribavirin. Their SVR was 90%[41]. As a result, this 
combination is recommended to be continued for 24 wk 
in treatment-experienced HCV genotype-1 infection with 
compensated cirrhosis. Patients with HCV genotype-4 
with or without compensated cirrhosis were treated 
with Ledispavir-Sofosbuvir combination with or without 
ribavirin. Overall SVR12 was 95.4% in non-cirrhotics 
and 93.2% in cirrhotics[42]. Patients with HCV genotype 5 
with or without compensated cirrhosis were treated with 
Ledspavir-Sofosbuvir for 12 wk in a multi-center open-
label study. The SVR12 was 95% in both treatment-naïve 
and treatment-experienced groups; 89% of cirrhotics 
and 97% of non-cirrhotics achieved SVR12[43]. A small 
study showed when fixed dose combination of Ledispavir-
Sofosbuvir was given to treatment-naïve and treatment-
experienced patients with HCV genotype 6 infection for 
12 wk, 96% of them achieved SVR12[44]. At the present 
time, Ledispavir-Sofosbuvir combination is indicated for 
the treatment of HCV genotype 1, 4, 5 and 6 infections 
with or without compensated cirrhosis. It is also used in 
HCV genotype 1 infection with decompensated cirrhosis 
in combination with ribavirin. Post liver transplant 
recipients who have HCV genotype 1 or 4 infection with 
or without compensated cirrhosis can be treated with 
Ledispavir-Sofosbuvir plus ribavirin for 12 wk. In one 
study, 96% of patients who had F-0 to F-3 fibrosis or 
compensated cirrhosis achieved SVR[45].
Common side effects of Harvoni include headache, 
fatigue, nausea and diarrhea. Harvoni like other DAAs 
can reactivate HBV if the patient is HBV/HCV co-infected 
and not receiving anti-HBV therapy. So prior to initiation 
of Harvoni, serological evidence of HBV infection should 
be tested and treated if positive.
Drug-drug interaction: Co-administration of amio-
darone with Harvoni may cause serious symptomatic 
bradycardia. Dose adjustment or regimen change may 
be required for certain medications. These include 
antiarrhythmic drug digoxin, HMG Co-A reductase inhi-
bitor rosuvastatin, anticoagulant warfarin, acid reducing 
agents proton pump inhibitors, H2 receptor antagonists, 
antacids, anticonvulsants phenytoin, phenobarbital, 
carbamazepine, oxcarbazepine, antimycobacterials 
rifampin, rifabutin, rifapentine, anti-HCV medication 
simeprevir, anti-HIV medications tenofovir DF, 
emtricitabine, cobicistat, elvitegravir, tipranavir/ritonavir, 
regimen containing tenofovor DF and an HIV protease 
inhibitor/ritonavir or cobicistat: darunavir/ritonavir or 
cobicistat + emtricitabine/tenofovir DF, atazanavir/
ritonavir or cobicistat + emtricitabine/tenofovir DF, 
lopinavir/ritonavir + emtricitabine/tenofovir DF, and 
herbal supplement St. John’s Wort[46]. 
Ombitasvir is a NS5A inhibitor. After absorption, 
it binds to NS5A and blocks the activity of NS5A to 
prevent HCV replication. It is used in combination with 
paritaprevir, retinovir and dasabuvir with or without 
ribavirin. In Viekira pak, paritaprevir, ritonavir and 
ombitasvir packaged in a single table, and dasabuvir is a 
different tablet. The daily dose of Viekira pak is 2 tablets 
of paritaprevir, ritonavir and ombitasvir in the morning, 
and one tablet of dasabuvir twice a day. In Viekira XR, 
each tablet contains partaprevir, ritonavir, ombitasvir and 
dasabuvir. 3 tablets have to be taken daily for 12 to 24 
wk.
Daclatasvir is a highly selective pangenotypic NS5A 
inhibitor[47]. It has dual mode of action as it binds to the 
N-terminal of NS5A and thus prevents viral replication 
and viral assembly. It is the first oral medication used in 
combination with sofosbuvir for 12 wk for the treatment 
of hepatitis C genotype 3 infection. HCV genotype 3 is the 
most aggressive (having faster disease progression) and 
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most treatment resistant genotype affecting 12% of all 
HCV genotypes in United States. In Ally-3 trial, a 12 wk 
therapy of daclatasvir plus sofosbuvir achieved SVR12 in 
96% of non-cirrhotic patients infected with HCV genotype 
3 irrespective of prior treatment experience[48]. In Ally 
3+ trial, daclatasvir plus sofosbuvir plus ribavirin were 
given to treatment-naïve and treatment-experienced 
patients with advanced fibrosis or compensated cirrhosis 
for 12 or 16 wk. The SVR12 was 90% in the 12 wk and 
92% in the 16 wk group[49]. In Ally-2 trial, 12 wk course 
of daclatasvir plus sofosbuvir achieved SVR12 of 97% 
in patients infected with HCV genotype 1 to 4 coinfected 
with HIV[50]. The efficacy of daclatasvir plus sofosbuvir 
in cirrhotic patients infected with HCV genotype 1 to 6 is 
being studied in Ally-1 trial[51]. 
Common side effects include headache, fatigue, 
nausea and diarrhea. Certain drugs are contraindicated 
to be used with daclatasvir. These include anticonvulsants 
phenytoin, carbamazepine, antimycobacterial agent 
rifampin and herbal supplement St. John’s Wort. 
Drug-drug interactions: Medications which can cause 
significant drug interactions with daclatasvir include 
statins, digoxin, dabigatran, ketoconazole, itraconazole, 
clarithromycin, nafcillin, dexamethasone, buprenorphine, 
modafinil, bosentan, anti-HIV medications - protease 
inhibitors: atazanavir with ritonavir, indinavir, nelfi-
navir, saquinavir; Non-nucleoside reverse transcriptase 
inhibitors: Efavirenz Etravirine Nevirapine; and cobi-
cistat-containing antiretroviral: atazanavir/cobicistat, 
elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil 
fumarate[52].
Elbasvir is a potent NS5A inhibitor. It is used in 
combination with grazoprevir which is a NS3/4A pro-
tease inhibitor. The combination is effective against 
HCV genotypes 1 and 4. Elbasvir can be less effective 
when there are many resistance- associated variants 
or substitutions (RAVs or RASs) of NS5A[53]. Elbasvir-
Grazoprevir can be taken in empty stomach or with 
food. In C-EDGE trial, treatment-naïve HCV infected 
patients had a good response (SVR12) rate to 12 wk 
therapy of Elbasvir-Grazoprevir: 92% with genotype 
1a, 99% with genotype 1b, 100% with genotype 4 and 
80% with genotype 6; 97% in cirrhotics and 94% in 
non-cirrhotics[54]. In C-EDGE TE trial, patients with prior 
exposure to pegylated interferon and ribavirin, Elbasvir/
Grazoprevir with or without ribavirin was highly effective 
in inducing an SVR12 in patients with HCV genotype 1, 4 
and 6 including patients with cirrhosis[55]. 
Velpatasvir is a pangenotypic second generation 
NS5A inhibitor and is much more potent with a higher 
barrier to resistance than the first generation NS5A 
inhibitors (ledispavir and Daclatasvir). It acts as a 
defective substrate for NS5A and prevents HCV rep-
lication. It is used as a fixed dose co-formulation with 
sofosbuvir (Epclusa). In a double blind placebo-controlled 
study, sofosbuvir-velpatasvir combination was given 
daily for 12 wk to untreated and previously treated 
patients with HCV infection genotypes 1-6 including 
those with compensated cirrhosis. The SVR was 99%[56]. 
Another study showed that when sofosbuvir-velpatasvir 
combination plus ribavirin were given daily for 12 wk to 
decompensated cirrhotics (Child - Pugh - Turcotte class B) 
due to HCV infection genotype 1-6, the SVR was 94%[57].
Common side effects of Epclusa include headache, 
fatigue, insomnia, nausea and diarrhea. If the patient is 
HBV/HCV coinfected and not receiving ant-HBV therapy, 
administration of Epclusa may cause reactivation of HBV 
and fulminant hepatitis during or after treatment with 
Epclusa.
Drug-drug interactions: Similar to Harvoni, co-
administration of Amiodarone with Epclusa may lead 
serious symptomatic bradycardia. Dose alteration or 
regimen change may be recommended for certain 
medications. These include acid suppressant agents 
proton pump inhibitors, H2 receptor blockers, antacids 
(aluminum and magnesium hydroxide), HMG Co-A 
reductase inhibitors atorvastatin, rosuvastatin, anti-
arrhythmic drug digoxin, anticonvulsants phenytoin, 
phenobarbital, carbamazepine, oxcarbazepine, anti-
mycobacterials rifampin, rifabutin, rifapentine, anti-HIV 
medications efavirenz, etravirine, nevirapine, tipranavir/
ritonavir, Regimens containing tenofovir DF, anti-cancer 
medication topotecan, and herbal supplement St. John’s 
wort[58].
Pibrentasvir is a 2ed generation NS5A inhibitor cofor-
mulated with glecaprevir (Mavyret). As mentioned before 
glecaprevir/pibrentasvir combination is pangenotypic 
and can be used in severe renal failure, including he-
modialysis patients.
NS5B inhibitors
They act on the catalytic site of NS5B polymerase. 
They cause HCV RNA chain termination after being 
incorporated into the RNA chain. Nucleotide NS5B 
inhibitors are already activated. They act on the active 
site of NS5B polymerase. Non-Nucleoside NS5B in-
hibitors need to be activated by cellular kinase 3 times 
to become the triphosphate which is the active form. 
They act on different allosteric sites (thumb, finger and 
palm domains) to downregulate NS5B polymerase[59]. 
Nucleotide NS5B inhibitors are moderately potent DAA 
with pangenotypic coverage and have high barrier to 
resistance. Non-nucleoside NS5B inhibitors are mo-
derately potent DAA with limited genotypic coverage and 
low barrier to resistance.
Sofosbuvir is a nucleotide NS5B polymerase inhibi-
tor[60]. It is coformulated with Ledipasvir for the treatment 
of hepatitis C genotype 1, 4, 5 and 6 infection. A meta-
analysis showed no additional benefit when ribavirin 
was added to sofosbuvir/ledipasvir for the treatment 
genotype 1 infection[61]. As mentioned before, sofosbuvir/
daclatasvir combination is effective for the treatment 
of hepatitis C genotypes 1 to 4[62]. Patients with HCV 
genotypes 2 and 3 infections were treated with sofosbuvir 
and ribavirin for 12 wk and 24 wk respectively: SVR 12 
was 93% for genotype 2 infection, and 85% for genotype 
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3 infection. In non-cirrhoitc HCV genotype 3 infection, the 
SVR was 91% whereas in cirrhotic genotype 3 infection, 
the SVR was 68%[63]. Sofosbuvir has been coformulated 
with other NS5A inhibitor or NS3/4A protease inhibitor to 
make the combination more effective against HCV and 
also pangenotypic.
Common side effects of Sofosbuvir include headache, 
nausea, insomnia and fatigue. Reactivation of HBV with 
fulminant hepatitis can occur if the patient is HBV/HCV 
co-infected and not receiving anti-HBV therapy. 
Drug-drug interactions: Dose alteration or change 
in regimen is recommended for certain medications. 
These include anticonvulsants phenytoin, phenobarbital, 
carbamazepine, oxcarbazepine, anti-HIV medications 
tipranavir/ritonavir, antimycobacterial agents rifampin, 
rifabutin, rifapentine, and herbal supplement St. John’s 
Wort[64].
Dasabuvir is a non-nucleoside NS5B polymerase 
inhibitor. It is used in combination with Paritaprevir/
ritonavir-ombitasvir ((in Viekira Pak and Viekira XR) 
with or without ribavirin for the treatment of hepatitis 
C genotype 1 infection with or without compensated 
cirrhosis (Child-Pugh A). It binds to the palm domain 
of NS5B, and thus prevents elongation of HCV RNA. 
The binding site is poorly conserved across other HCV 
genotypes. As a result, Dasabuvir is only effective against 
HCV genotype 1 infection. Every year new DAAs are 
being added in our clinical practice. Currently, the various 
DAAs available in formulation are as follows (Table 1).
Individualized treatment options
In 2018, we treat hepatitis C with combination of at least 
two DAAs or one DAA with ribavirin. Several factors are 
to be considered before planning treatment for hepatitis C. 
These include HCV genotype, HCV viral load, treatment-
naïve or treatment-experienced (PEG/RIBA, NS3/4A 
protease inhibitor, NS5A inhibitor, NS5B inhibitor) patient, 
cirrhotic or non-cirrhotic patient, absence or presence of 
baseline NS5A resistance-associated substitutions (RASs), 
patient’s current medications considering any drug-drug 
interactions (DDI), patient’s renal function, co-infection 
with HIV, post-liver transplant infection, and of course, 
patient’s insurance and financial status. Guidelines for the 
treatment of hepatitis C was updated by the European 
Association for the Study of Liver (EASL) in 2016 and 
the American Association for the Study of Liver Diseases 
(AASLD) and the Infectious Diseases Society of America 
(IDSA) in 2017[65,66]. Individualized treatments as per the 
AASLD guidelines[66] are listed in Tables 2 and 3.
Genotype 1 infection-treatment-experienced
Glecaprevir/Pibrentasvir (Mavyret): Duration of treatment 
depends on previous regimen and presence or absence 
of compensated cirrhosis. Elbasvir/Grazoprevir (Zepatier): 
duration depends on viral load irrespective of no 
cirrhosis or compensated cirrhosis as per EASL guideline. 
Ledipasvir/Sofosbuvir (Harvoni): Applicable for both 
non-cirrhotics and compensated cirrhotics. Sofosbuvir/
Velpatasvir (Epclusa): treatment is same for both non-
cirrhotics and compensated cirrhotics. Daclatasvir 
(Daklinza) plus Sofosbuvir (Sovaldi): applicable for both 
non-cirrhotics and compensated cirrhotics. Paritaprevir/
ritonavir/ombitasvir and dasabuvir (in Viekira Pak and 
Viekira XR) with weight-based ribavirin (Tables 3-6).
HCV/HIV Co-infection
Twenty percent to 30% of the 34 million HIV infected 
individuals in the world are co-infected with HCV[67]. HCV/
HIV co-infection carries increased morbidity and mortality 
including advanced hepatic fibrosis and cirrhosis[68]. 
HCV/HIV co-infected patients have higher HCV viral 
load, more chance of developing chronic HCV infection 
and rapid development of advanced liver disease than 
HCV mono-infected patients. The main challenge of 
treating these group of patients is drug-drug interactions, 
i.e., interactions between anti-HCV DAAs and anti-
retroviral medications[69]. But the SVR and side effects 
are similar to those of HCV mono-infected patients[70]. 
Ideally, HCV/HIV co-infection should be managed by 
or in collaboration with a HIV practitioner. No change in 
antiretroviral therapy should be done without consultation 
of the HIV practitioner. Certain guidelines given by AASLD 
and IDSA are as follows[66]: (1) Ledipasvir/Sofosbuvir 
(Harvoni): This combination has certain interactions 
with anti-retrovirals mentioned before. As it increases 
serum level of tenofovir disoproxil fumerate which may 
cause renal toxicity, renal function should be monitored 
and tenofovir disoproxil fumerare should be used with 
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No. Trade name Generic name with doses
1 Sovaldi Sofosbuvir 400 mg
2 Olysio Simeprevir 150 mg
3 Daklinza Daclatasvir 30 mg/60 mg/90 mg
4 Harvoni Ledipasvir 90 mg/Sofosbuvir 400 mg
5 Viekira Pak 1 d pack contains Paritaprevir 75 mg/Ombitasvir 12.5 mg/Ritonavir 50 mg tablet × 2 and Dasabuvir 250 mg tablet × 2
6 Viekira XR Extended release tablet contains Dasabuvir 200 mg/ombitasvir 8.33 mg/Paritaprevir 50 mg/Ritonavir 33.33 mg
7 Technivie Ombitasvir 12.5 mg/Paritaprevir 75 mg/Ritonavir 50 mg
8 Epclusa Sofosbuvir 400 mg/ Velpatasvir 100 mg
9 Zepatier Elbasvir 50 mg/ Grazoprevir 100 mg
10 Mavyret Glecaprevir 100 mg/ Pibrentasvir 40 mg
11 Vosevi Sofosbuvir 400 mg/Velpatasvir 100 mg/Voxilaprevir 100 mg
Table 1  Direct acting anti-viral agents with posology
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GFR > 60 mL/min. Tenofovir alafenamide could be an 
alternative option; (2) Paritaprevir/ritonavir/ombitasvir 
and dasabuvir (in Viekira Pak and Viekira XR): The 
anti-HIV medications which do not have substantial 
interaction with Vikira Pak and Viekira XR include 
atazanavir, dolutegravir, emtricitabine, enfuvirtide, 
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No. First line therapy Alternative regimen
Genotype 1a infection - treatment-naïve and non-cirrhotic
   1 Glecaprevir/Pibrentasvir (Mavyret) - 8 wk Paritaprevir/ritonavir/ombitasvir and dasabuvir (in Viekira 
Pak and Viekira XR) with weight-based ribavirin - 12 wk
   2 Elbasvir/Grazoprevir (Zepatier) for patients without baseline NS5A RAVs for 
Elbasvir - 12 wk
Simeprevir (Olysio) plus Sofosbuvir (Sovaldi) - 12 wk
   3 Ledipasvir/Sofosbuvir (Harvoni) - 12 wk < Ledipasvir/Sofosbuvir (Harvoni) - 8 
wk in non-black, HIV-uninfected individuals with serum HCV RNA < 6 million 
units/mL
Daclatasvir(Daklinza) plus Sofosbuvir (Sovaldi) - 12 wk
   4 Sofosbuvir/Velpatasvir (Epclusa) - 12 wk Elbasvir/Grazoprevir (Zepatier) with weight-based ribavirin 
for patients with baseline NS5A RAVs for Elbasvir - 16 wk
Genotype 1a infection - treatment-naïve with compensated cirrhosis
   1 Glecaprevir/Pibrentasvir (Mavyret) - 12 wk Elbasvir/Grazoprevir (Zepatier) with weight-based ribavirin 
for patients with baseline NS5A RASs for Elbasvir - 16 wk
   2 Elbasvir/Grazoprevir (Zepatier) for patients without baseline NS5A RAVs for 
Elbasvir - 12 wk
   3 Ledipasvir/Sofosbuvir (Harvoni) - 12 wk
   4 Sofosbuvir/Velpatasvir (Epclusa) - 12 wk
Genotype 1b infection - treatment-naïve and non-cirrhotic
   1 Glecaprevir/Pibrentasvir (Mavyret) - 8 wk Paritaprevir/ritonavir/ombitasvir and dasabuvir (in Viekira 
Pak and Viekira XR) - 12 wk
   2 Elbasvir/Grazoprevir (Zepatier) - 12 wk Simeprevir (Olysio) plus Sofosbuvir (Sovaldi) - 12 wk
   3 Ledipasvir/Sofosbuvir (Harvoni) - 12 wk < Ledipasvir/Sofosbuvir (Harvoni - 8 
wk in non-black, HIV-uninfected individuals with serum HCV RNA < 6 million 
units/mL
Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi) - 12 wk
   4 Sofosbuvir/Velpatasvir (Epclusa) - 12 wk
Genotype 1b infection - treatment-naïve with compensated cirrhosis
   1 Glecaprevir/Pibrentasvir (Mavyret) - 12 wk Paritaprevir/ritonavir/ombitasvir and dasabuvir (in Viekira 
Pak and Viekira XR) - 12 wk
   2 Elbasvir/Grazoprevir (Zepatier - 12 wk
   3 Ledipasvir/Sofosbuvir (Harvoni) - 12 wk
   4 Sofosbuvir/Velpatasvir (Epclusa - 12 wk
Table 2  Genotype 1a and 1b infection - treatment-naïve (with compensated cirrhosis) and non-cirrhotic
RAVs: Resistance- associated variants; HIV: Human immunodeficiency virus; HCV: Hepatitis C virus.
IFN: Interferon; PI; Protease inhibitors; HCV: Hepatitis C virus.
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Table 3  Genotype 1 infection-treatment-experienced
Glecaprevir/Pibrentasvir (Mavyret): Duration of treatment depends on previous regimen and presence or absence of compensated cirrhosis.
   Previous regimen No cirrhosis Compensated cirrhosis
   Pegylated IFN, ribavirin and/or Sofosbuvir but no 
   prior exposure to NS3/4A PI or NS5A inhibitor
8 wk 12 wk
   NS3/4A PI but no prior exposure to NS5A inhibitor 12 wk 12 wk
   NS5A inhibitor but no prior exposure to NS3/4A PI 16 wk 16 wk
Elbasvir/Grazoprevir (Zepatier): Duration depends on viral load irrespective of no cirrhosis or compensated cirrhosis as per EASL guideline.
   Previous regimen HCV RNA ≤ 800000 IU/mL HCV RNA > 800000 IU/mL
   Pegylated IFN and ribavirin 12 wk without ribavirin 16 wk with ribavirin
Ledipasvir/Sofosbuvir (Harvoni): Applicable for both non-cirrhotics andcompensated cirrhotics.
   Previous regimen With ribavirin Without ribavirin
   PEG IFN and ribavirin 12 wk 24 wk
Sofosbuvir/Velpatasvir (Epclusa): Treatment is same for both non-cirrhotics and compensated cirrhotics.
   Previous regimen No cirrhosis Compensated cirrhosis
   PEG IFN and ribavirin 12 wk without ribavirin 12 wk without ribavirin
Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi): Applicable for both non-cirrhotics and compensated cirrhotics.
   Previous regimen With ribavirin Without ribavirin
   PEG IFN and ribavirin 12 wk 24 wk
Paritaprevir/ritonavir/ombitasvir and dasabuvir (in Viekira Pak and Viekira XR) with weight-based ribavirin.
   Previous regimen No cirrhosis Compensated cirrhosis
   PEG IFN and ribavirin 12 wk 24 wk
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lamivudine, raltegravir, and tenofovir; (3) Sofosbuvir/
Velpatasvir (Epclusa): Can have drug-drug interactions 
with anti-retrovirals mentioned before. As velpatasvir can 
increase the serum level of tenofovir disoproxil fumerate, 
renal function should be checked and tenofovir disoproxil 
fumerate should not be used with a GFR of less than 60 
mL/min. Tenofovir alafenamide could be used instead; (4) 
Elbasvir/Grazoprevir (Zepatier): Certain antiretrovirals do 
not have significant drug-drug interactions with elbasvir/
grazoprevir combinations. These include tenofovir, 
lamivudine, emtricitabine, abacavir, dolutegravir, 
raltegravir, rilpivirine, and enfuvirtide; (5) Glecaprevir/
Pibrentasvir (Mavyret): The anti-retrovirals which 
do not have significant drug-drug interactions with 
Glecaprevir/Pibrentasvir include lamivudine, tenofovir, 
emtricitabine, abacavir, dolutegravir, raltegravir, rilpivirine, 
and enfuvirtide; (6) Sofosbuvir/Velpatasvir/Voxilaprevir 
(Vosevi): Has some drug-drug interactions with certain 
anti-retrovirals mentioned before. But some of the anti-
retrovirals do not have significant interactions with 
this combination (Vosevi). These include lamivudine, 
emtricitabine, dolutegravir, enfuvirtide, raltegravir 
and rilpivirine; (7) Simeprevir (used in combination 
with another DAA): Does not have significant drug-
drug interactions with certain anti-retrovirals which 
include lamivudine, tenofovir, emtricitabine, abacavir, 
dolutegravir, raltegravir, rilpivirine, enfuvirtide and 
maraviroc; and (8) Daclatasvir (used in combination with 
another DAA): Has significant drug-drug interactions with 
certain anti-retrovirals mentioned before. Certain dose 
adjustment include: cobicistat/atazanavir (decrease dose 
to 30 mg/d), cobicistat/elvitegravir (decrease dose to 30 
mg/d), ritonavir/atazanavir (decrease dose to 30 mg/d), 
and efavirenz or etravirine (increase dose to 90 mg/d).
HCV infection in post-liver transplant patients
Recurrence of hepatitis C infection following liver 
transplantation is universal in all patients with pre-
transplantation viremia. The course varies from asymp-
tomatic infection to fibrosing cholestatic hepatitis[71]. 
About one third of post-transplant HCV-infected pa-
tients develop allograft cirrhosis 5 to 7 years after 
transplantation[72]. As per AASLD and IDSA guidelines 
published on September 21, 2017 the various treatment 
options are list in Table 7[66].
There are drug-drug interactions between DAA and 
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No. First line therapy Alternative regimen
Genotype 2 infection - treatment-naïve and non-cirrhotic
   1 Glecaprevir/Pibrentasvir (Mavyret) - 8 wk Daclatasvir(Daklinza) plus Sofosbuvir (Sovaldi) - 12 wk
   2 Sofosbuvir/Velpatasvir (Epclusa) - 12 wk
Genotype 2 infection - treatment-naïve with compensated cirrhosis
   1 Glecaprevir/Pibrentasvir (Mavyret) - 12 wk Daclatasvir(Daklinza) plus Sofosbuvir (Sovaldi) - 16 to 24 wk
   2 Sofosbuvir/Velpatasvir (Epclusa) - 12 wk
Genotype 3 infection - treatment-naïve and non- cirrhotic
   1 Glecaprevir/Pibrentasvir (Mavyret) - 8 wk Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi) - 12 wk
   2 Sofosbuvir/Velpatasvir (Epclusa - 12 wk
Genotype 3 infection - treatment-naïve with compensated cirrhosis
   1 Glecaprevir/Pibrentasvir (Mavyret) - 12 wk Vosevi - Sofosbuvir 400 mg/ Velpatasvir 100 mg/ Voxilaprevir 100 mg when Y93 is 
present - 12 wk
   2 Sofosbuvir/Velpatasvir (Epclusa) - 12 wk Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi) with or without weight-based 
ribavirin - 24 wk
Genotype 4 infection - treatment-naïve and non-cirrhotic
   1 Glecaprevir/Pibrentasvir (Mavyret) - 8 wk Ombitasvir 25 mg/Paritaprevir 150 mg/ Ritonavir 100 mg (Technivie) with weight-
based ribavirin - 12 wk
   2 Sofosbuvir/Velpatasvir (Epclusa) - 12 wk
   3 Elbasvir/Grazoprevir (Zepatier) - 12 wk
   4 Ledipasvir/Sofosbuvir (Harvoni) - 12 wk
Genotype 4 infection - treatment-naïve with compensated cirrhosis
   1 Sofosbuvir/Velpatasvir (Epclusa) - 12 wk Ombitasvir 25 mg/Paritaprevir 150 mg/ Ritonavir 100 mg (Technivie) with weight-
based ribavirin - 12 wk
   2 Glecaprevir/Pibrentasvir (Mavyret) - 12 wk
   3 Elbasvir/Grazoprevir (Zepatier) - 12 wk
   4 Ledipasvir/Sofosbuvir (Harvoni) - 12 wk
Table 4  Genotype 2-4 infection - treatment-naïve (with compensated cirrhosis) and non-cirrhotic
No. DAA No cirrhosis Compensated cirrhosis
1 Glecaprevir/Pibrentasvir (Mavyret)   8 wk 12 wk
2 Sofosbuvir/Velpatasvir (Epclusa) 12 wk 12 wk
3 Ledipasvir/Sofosbuvir (Harvoni) 12 wk 12 wk
Table 5  Genotype 5 or 6 infection - treatment-naïve with and without compensated cirrhosis
DAA: Direct acting anti-viral agent.
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calcineurin inhibitors: cyclosporine A and Tacrolimus. 
When Sofosbuvir is used with cyclosporine A, serum level 
of sofosbuvir is increased by 4.5 fold but GS -331007 
metabolite remains unchanged. So no dose adjustment 
is required[73]. Sofosbuvir has no drug interaction with 
Tacrolimus[74]. When Paritaprevir/ritonavir/ombitasvir 
and dasabuvir- (PrOD) in Viekira Pak and Viekira XR 
are used with cyclosporine A, there is 5.8 fold increased 
serum level of cyclosporine A suggesting use of 1/5th of 
dose of cyclosporine A and requirement of monitoring 
of serum level of cyclosporine A. When PrOD are used 
with tacrolimus, there is 57 fold increase in tacrolimus 
level in the blood, suggesting use of 0.5 mg of tacrolimus 
once a week, and monitoring of tacrolimus level in 
the blood[75]. When elbasvir/grazoprevir combination 
is used with cyclosporine A, there is 15 fold increases 
in grazoprevir level in the blood. As a result, this 
combination is not recommended to be used. When 
elbasvir/grazoprevir are used with tacrolimus, there is 
43% increase in tacrolimus level, and although no prior 
dose adjustment is required, frequent monitoring of 
tacrolimus level, tacrolimus-associated side effects and 
renal function should be done[76]. When glecaprevir/
pibrentasvir is used with higher dose (400 mg) of 
cyclosporine A, there is 5 fold increase in glecaprevir 
level in the blood. This combination is not recommended 
in patients requiring more than 100 mg of cyclosporine 
A[77]. When glecaprevir/pibrentasvir combination is used 
with tacrolimus, there is 1.45 fold increase in tacrolimus 
level suggesting no prior dose adjustment but tacrolimus 
level should be monitored. When sofosbuvir/velpatasvir/
voxilaprevir combination is used with cyclosporine A, 
there is 9.4 fold increase in voxilaprevir. This combination 
is not recommended[78].
October 27, 2018|Volume 10|Issue 10|
First line therapy Alternative regimen
Genotype 2 infection - treatment-experienced
   Pegylated IFN/ribavirin-experienced without 
   cirrhosis
Glecaprevir/Pibrentasvir (Mavyret) - 8 wk or 
Sofosbuvir/Velpatasvir (Epclusa) - 12 wk
Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi) - 12 
wk
   Pegylated IFN/ribavirin-experienced with 
   compensated cirrhosis
Sofosbuvir/Velpatasvir (Epclusa) - 12 wk or 
Glecaprevir/Pibrentasvir (Mavyret) - 12 wk
Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi) - 16 
to 24 wk
   Sofosbuvir plus ribavirin-experienced with or 
   without compensated cirrhosis
Sofosbuvir/Velpatasvir (Epclusa) - 12 wk or 
Glecaprevir/Pibrentasvir (Mavyret) - 12 wk
Genotype 3 infection - treatment-experienced
   Pegylated IFN/ ribavirin-experienced without 
   cirrhosis
Sofosbuvir/Velpatasvir (Epclusa) - 12 wk Daclatasvir (Daklinza) plus Sofosbuvir (Sovaldi) - 12 
wk or Glecaprevir/Pibrentasvir (Mavyret) - 16 wk 
or Sofosbuvir/Velpatasvir/Voxilaprevir - 12 wk
   Pegylated IFN/ ribavirin-experienced with 
   compensated cirrhosis
Elbasvir/Grazoprevir (Zepatier) - 12 wk or 
Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) 
-12 wk
Sofosbuvir/Velpatasvir (Epclusa) plus weight-
based ribavirin - 12 wk or Glecaprevir/Pibrentasvir 
(Mavyret) - 16 wk
   DAA-experienced including NS5A inhibitors 
   with or without compensated cirrhosis
Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) 
- 12 wk or in case of NS5A inhibitor failure and 
cirrhosis - Vosevi plus weight-based Ribavirin - 
12 wk
Genotype 4 infection - treatment-experienced
   Pegylated IFN/ ribavirin-experienced without 
   cirrhosis
Sofosbuvir/Velpatasvir (Epclusa) -12 wk or 
Glecaprevir/Pibrentasvir (Mavyret) - 8 wk or 
Elbasvir/Grazoprevir (Zepatier) in virologic 
relapse - 12 wk or Ledipasvir/Sofosbuvir 
(Harvoni) - 12 wk
Ombitasvir 25 mg/Paritaprevir 150 mg/Ritonavir 
100 mg plus weight based Ribavirin - 12 wk or 
Elbasvir/Grazoprevir (Zepatier) with weight-based 
Ribavirin (in case of prior on-treatment virologic 
failure) - 16 wk
   Pegylated IFN/ ribavirin-experienced with 
   compensated cirrhosis
Sofosbuvir/Velpatasvir (Epclusa) - 12 wk or 
Elbasvir/Grazoprevir (Zepatier) in virologic 
relapse - 12 wk or Glecaprevir/Pibrentasvir 
(Mavyret) - 12 wk
Ombitasvir 25 mg/Paritaprevir 150 mg/ Ritonavir 
100 mg plus weight based Ribavirin - 12 wk or 
Elbasvir/Grazoprevir (Zepatier) with weight-based 
Ribavirin (in case of prior on-treatment virologic 
failure - 16 wk or Ledipasvir/Sofosbuvir (Harvoni) 
plus weight-based Ribavirin) - 12 wk
   DAA-experienced including NS5A inhibitors 
   with or without compensated cirrhosis
Sofosbuvir/Velpatasvir/Voxilaprevir (Vosevi) - 
12 wk
Genotype 5 or 6 infection - treatment-experienced (recommended regimen)
   Pegylated IFN/ ribavirin-experienced with or 
   without compensated cirrhosis
Glecaprevir/Pibrentasvir (Mavyret) - 8 wk 
for patients without cirrhosis and 12 wk 
for patients with compensated cirrhosis 
or Ledipasvir/Sofosbuvir (Harvoni) plus 
weight-based Ribavirin - 12 wk or Sofosbuvir/
Velpatasvir (Epclusa) - 12 wk
   DAA-experienced including NS5A inhibitors 
   with or without compensated cirrhosis
Sofosbuvir/Velpatasvir/ Voxilaprevir (Vosevi) 
- 12 wk
Table 6  Genotype 2-6 infection - treatment-experienced
IFN: Interferon; DAA: Direct acting anti-viral agent.
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DAA and hepatocellular carcinoma 
Concern emerged after the study done by Reig et al[79] 
in 2016 showing higher rate of hepatocellular carcinoma 
(HCC) recurrence after DAA treatment in patients with 
prior HCC. Subsequently few studies were done to 
evaluate this finding. Large VA cohort study did not find 
any increased risk of developing HCC after DAA therapy[80]. 
Fortunately, the concern has lost its importance. But all 
cirrhotic patients should be under surveillance for HCC 
after DAA therapy. 
DAA failure
DAA failure or relapse has occurred in less than 10% of 
HCV infected patients in clinical trials. In a multicenter 
real life study, the overall failure rate was found to 
be 3.6%[81]. As mentioned before, HCV exists as a 
quasispecies with production of various genetically 
distinct variants due to replication errors. Due to this 
high mutation rate of HCV genome, changes in the 
critical coding regions may occur making the virus less 
susceptible to anti-HCV therapy. Viral variants containing 
polymorphisms or substitutions resistant to DAA are 
also called baseline resistant-associated substitutions 
(RASs) and they exist in a small percentage of patients 
with chronic HCV infection prior to anti-HCV therapy. 
Sometimes RASs develop after initiation of DAA therapy 
when they are called treatment-emergent or treatment-
selected RASs. Subtherapeutic DAA level may predispose 
to the development of RASs. NS5A and NS3 RASs are 
frequently seen in cases of failure of DAA containing 
NS5A or NS3 inhibitor[82]. On the other hand, there is 
rare development of NS5B RASs even after exposure to 
a failed DAA therapy containing. NS5B inhibitor, possibly 
due to binding of NS5B inhibitor to the highly conserved 
catalytic site of the viral genome making generation of 
RASs extremely difficult[83]. 
AASLD and IDSA recommend testing for NS5A RASs 
if DAAs containing NS5A inhibitors fail[82]. Testing for 
baseline NS5A RASs is recommended in patients infected 
with HCV genotype 1a prior to initiation of elbasvir and 
grazoprevir therapy[84]. Baseline NS5A RASs testing 
should also be considered in patients with cirrhosis of 
liver due to HCV genotype 1a infection prior to sofosbuvir 
plus daclatasvir therapy[85]. NS5A RASs testing should 
be considered in certain situations: (1) treatment-naïve 
HCV genotype 3 infection with compensated cirrhosis 
of liver prior to treatment with either Sofosbuvir/
Velpatasvir (Epclusa) for 12 wk or Daclatasvir (Daklinza) 
plus Sofosbuvir (Sovaldi) for 24 wk; (2) treatment-
experienced HCV genotype 3 infection without cirrhosis 
prior to treatment with Daclatasvir(Daklinza) plus 
Sofosbuvir (Sovaldi) for 12 wk; and (3) treatment-
experienced HCV genotype 3 infection with or without 
cirrhosis prior to treatment with Sofosbuvir/Velpatasvir 
(Epclusa) for 12 wk. If Y93H is found, weight-based 
ribavirin should be added[82]. DAA failure has been 
associated with certain predisposing factors like presence 
of RASs, sofosbuvir/ribavirin treatment, HCV genotype 3, 
and cirrhosis of liver[81,86].
CONCLUSION
DAAs have changed the treatment plan and outcome of 
chronic hepatitis C infection in this pegylated interferion 
free era. There are various DAAs available in the market 
and these include second generation NS3/4A protease 
inhibitors, NS5A and NS5B inhibitors. AASLD, IDSA and 
EASL recommend combination of DAAs with or without 
ribavirin. As the success rate is high, side effects are 
low, drug-drug interactions are less, and duration of 
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Genotype Treatment-naïve and - experienced patients 
with HCV infection in the allograft without 
cirrhosis
Treatment-naïve and - experienced patients 
with HCV infection in the allograft with 
compensated cirrhosis
Treatment-naïve and - experienced patients 
with HCV infection in the allograft with 
decompensated cirrhosis
Recommended therapy
   1, 4, 5 or 6 Glecaprevir/Pibrentasvir (Mavyret) - 12 wk or 
Ledipasvir/Sofosbuvir (Harvoni) for 12 wk
Ledipasvir/Sofosbuvir (Harvoni) with 
weight-based ribavirin
- 12 wk
Ledipasvir/Sofosbuvir (Harvoni) with initial 
low dose of ribavirin (600 mg), increase the 
dose as tolerated - 12 wk
   2 or 3 Glecaprevir/Pibrentasvir (Mavyret) - 12 wk 
or Daclatasvir (Daklinza) plus Sofosbuvir 
(Sovaldi) with initial low dose of ribavirin (600 
mg), increase the dose as tolerated for 12 wk
Daclatasvir (Daklinza) plus Sofosbuvir 
(Sovaldi) with initial low dose of ribavirin (600 
mg), increase the dose as tolerated - 12 wk
Daclatasvir (Daklinza) plus Sofosbuvir 
(Sovaldi) with initial low dose of ribavirin 
(600 mg), increase the dose as tolerated for 12 
wk or Sofosbuvir/Velpatasvir (Epclusa) with 
weight-based ribavirin - 12 wk
Alternative therapy
   1, 4, 5 or 6 Daclatasvir (Daklinza) plus Sofosbuvir 
(Sovaldi) with initial low dose of ribavirin 
(600 mg), increase the dose as tolerated for 
12 wk or HCV genotype 1 or 4 infection only: 
Simeprevir (Olysio) plus Sofosbuvir (Sovaldi) 
with or without weight-based ribavirin
Daclatasvir (Daklinza) plus Sofosbuvir 
(Sovaldi) with initial low dose of ribavirin 
(600 mg), increase the dose as tolerated for 
12 wk or HCV genotype 1 or 4 infection only: 
Simeprevir (Olysio) plus Sofosbuvir (Sovaldi) 
with or without weight-based ribavirin
   2 or 3 Glecaprevir/Pibrentasvir (Mavyret) for 12 
wk or Sofosbuvir/Velpatasvir (Epclusa) with 
weight-based ribavirin for 12 wk
Table 7  Recommended and alternative therapy
HCV: Hepatitis C virus.
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therapy is relatively short, more and more patients are 
getting treatment for the cure of hepatitis C infection. 
Some DAAs require preliminary testing to find out 
the effectiveness of that particular DAA, for example 
Q80K polymorphism in case of Simeprevir, and NS5A 
resistance testing in case of elabasvir. HBV co-infection 
testing should be done prior to initiation of any DAA 
therapy to prevent fulminant hepatitis and liver failure. 
Drug-drug interaction, and specific conditions like HCV/
HIV co-infection and HCV infection in post-liver transplant 
patients should considered before initiating any treatment 
plan. Although DAA can eradicate HCV infection, it 
does not decrease the chance of developing HCC in 
cirrhotic patients. So they should be under regular HCC 
surveillance. The next challenge will be the development 
of HCV vaccine to reduce the incidence of HCV infection 
in the world.
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